Immutep Limited Quick Ratio (IMMP) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Immutep Limited  (NASDAQ: IMMP)

Immutep Limited's Quick Ratio

IMMP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 5.28 below Immutep Limited's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 161 other companies have achieved higher Quick Ratio than Immutep Limited in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 208 to 530.

Explain Quick Ratio?
How much Cash & cash equivalents IMMP´s has?
What are IMMP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMMP Quick Ratio (Jun 30 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Jun 30 2024)
Q4
Y / Y Current Liabilities Change 19.78 % 19.78 % 21.67 % 21.67 % 7.53 %
Y / Y Cash & cash equivalent Change -58.98 % -58.98 % -58.98 % -58.34 % 31.37 %
Quick Ratio MRQ 5.28 5.28 3.47 5.28 15.43
IMMP's Total Ranking # 530 # 208 # # #
Seq. Current Liabilities Change 0 % -34.27 % 0 % 82.22 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % -34.27 % -37.6 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 162
Healthcare Sector # 268
Overall Market # 530


Quick Ratio Statistics
High Average Low
15.43 9.48 3.13
(Jun 30 2024)   (Jun 30 2019)




Financial Statements
Immutep Limited's Current Liabilities $ 8 Millions Visit IMMP's Balance sheet
Immutep Limited's Cash & cash equivalent $ 44 Millions Visit IMMP's Balance sheet
Source of IMMP's Sales Visit IMMP's Sales by Geography


Cumulative Immutep Limited's Quick Ratio

IMMP's Quick Ratio for the trailling 12 Months

IMMP Quick Ratio

 (Jun 30 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 20.91 % 18.62 % 16.26 % 11.92 % 7.4 %
Y / Y Cash & cash equivalent TTM Growth -58.77 % -42.61 % -24.53 % -4.16 % 31.28 %
Quick Ratio TTM 4.74 6.46 8.29 10.51 13.89
Total Ranking TTM # 2507 # 2757 # # #
Seq. Current Liabilities TTM Growth 3.38 % 3.5 % 6.1 % 6.5 % 1.42 %
Seq. Cash & cash equivalent TTM Growth -24.13 % -19.44 % -16.28 % -19.43 % 5.61 %

Quick ratio ranking by company, industry and sector >> Back to IMMP Financial Strength Comparisons >> Go to Compare IMMP Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $8.39 millions, cumulative Quick Ratio decreased to 4.74 below the Immutep Limited average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 390 other companies have achieved higher Quick Ratio than Immutep Limited. While Quick Ratio overall ranking has improved so far to 2507, from total ranking during the twelve months ending third quarter 2025 at 2757.

Explain Quick Ratio?
How much Cash & cash equivalents IMMP´s has?
What are IMMP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 391
Healthcare Sector # 784
Within the Market # 2507


trailing twelve months Quick Ratio Statistics
High Average Low
15.43 9.92 3.13
(Jun 30 2024)   (Jun 30 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Eupraxia Pharmaceuticals Inc   14.52 $ 80.563  Millions$ 5.550  Millions
Astria Therapeutics Inc   14.36 $ 259.178  Millions$ 18.044  Millions
Cryoport inc   14.20 $ 428.071  Millions$ 30.149  Millions
89bio Inc   14.17 $ 561.164  Millions$ 39.611  Millions
Rezolute Inc   14.09 $ 167.858  Millions$ 11.912  Millions
Lava Therapeutics Nv  13.97 $ 82.580  Millions$ 5.912  Millions
Aprea Therapeutics Inc   13.82 $ 16.532  Millions$ 1.196  Millions
Boundless Bio Inc   13.80 $ 127.148  Millions$ 9.213  Millions
Aardvark Therapeutics Inc   13.76 $ 141.820  Millions$ 10.310  Millions
Climb Bio Inc   13.65 $ 84.703  Millions$ 6.205  Millions
Nuvalent Inc   13.38 $ 1,005.598  Millions$ 75.147  Millions
Lite Strategy Inc   13.30 $ 18.011  Millions$ 1.354  Millions
Cartesian Therapeutics Inc   13.08 $ 160.324  Millions$ 12.256  Millions
Rapt Therapeutics Inc   12.95 $ 168.947  Millions$ 13.043  Millions
Medicinova Inc   12.94 $ 34.260  Millions$ 2.648  Millions
Eledon Pharmaceuticals Inc   12.92 $ 209.429  Millions$ 16.211  Millions
Arvinas Inc   12.83 $ 861.200  Millions$ 67.100  Millions
Dianthus Therapeutics Inc   12.81 $ 257.389  Millions$ 20.093  Millions
Pliant Therapeutics Inc   12.77 $ 262.873  Millions$ 20.591  Millions
Lipocine Inc   12.38 $ 17.936  Millions$ 1.449  Millions
Akero Therapeutics Inc   12.29 $ 742.315  Millions$ 60.401  Millions
Pmv Pharmaceuticals Inc   12.26 $ 142.274  Millions$ 11.607  Millions
Avalo Therapeutics Inc   12.23 $ 113.282  Millions$ 9.259  Millions
Ideaya Biosciences Inc   12.17 $ 669.738  Millions$ 55.020  Millions
Connect Biopharma Holdings Limited  12.16 $ 40.632  Millions$ 3.342  Millions
Arrivent Biopharma inc   12.06 $ 235.687  Millions$ 19.538  Millions
Immunome Inc   11.72 $ 268.036  Millions$ 22.878  Millions
Forte Biosciences Inc   11.58 $ 106.144  Millions$ 9.170  Millions
Onkure Therapeutics Inc   10.97 $ 83.374  Millions$ 7.597  Millions
Oramed Pharmaceuticals Inc  10.94 $ 40.415  Millions$ 3.693  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.